| Document Type
|
:
|
BL
|
| Record Number
|
:
|
865269
|
| Title & Author
|
:
|
Myelodysplastic syndromes : : diagnosis -- prognosis -- therapy /\ Uwe Platzbecker, Pierre Fenaux, editors.
|
| Publication Statement
|
:
|
Cham, Switzerland :: Springer,, 2018.
|
| Series Statement
|
:
|
Hematologic malignancies
|
| Page. NO
|
:
|
1 online resource
|
| ISBN
|
:
|
3319768786
|
|
|
:
|
: 3319768794
|
|
|
:
|
: 9783319768786
|
|
|
:
|
: 9783319768793
|
|
|
:
|
9783319768786
|
| Contents
|
:
|
Intro; Contents; Part I: Diagnostics and Prognosis; 1: Morphology andFlow Cytometry; 1.1 MDS Nomenclature: WHO2016; 1.2 Peripheral Blood; 1.3 Bone Marrow; 1.3.1 Counting Blasts; 1.3.2 Features ofDysplasia; 1.3.3 Iron Staining; 1.4 Special Subtypes ofMDS; 1.4.1 Hypoplastic MDS andMDS withMyelofibrosis; 1.4.2 ICUS andIDUS; 1.5 Flow Cytometry; References; 2: Diagnosis andPrognosis: Molecular; 2.1 Introduction; 2.2 Cytogenetics; 2.2.1 Recurrent Cytogenetic Abnormalities; 2.2.1.1 Chromosome 5q Deletions; 2.2.1.2 Chromosome 7 Abnormalities; 2.2.2 Clinical Implications.
|
|
|
:
|
2.2.2.1 Diagnosis andClassification2.2.2.2 Clinical Features: Genotype Phenotype Correlation; 2.2.2.3 Prognosis; 2.2.2.4 Therapeutic Implications; 2.3 Gene Mutations; 2.3.1 Recurrent Mutated Pathways; 2.3.1.1 Epigenetic Regulators: DNA Methylation andHistone Modification; 2.3.1.2 Splicing Factors; 2.3.1.3 Transcriptional Regulators, Signal Transducers andTyrosine Kinases; 2.3.1.4 TP53 Alterations; 2.3.1.5 Cohesin Complex; 2.3.2 Clinical Implications; 2.3.2.1 Diagnosis andClassification; 2.3.2.2 Clinical Features Genotype- Phenotype Correlation; 2.3.2.3 Prognosis.
|
|
|
:
|
2.3.2.4 Therapeutic Implications: Novel Targeted Therapy andPredictors ofResponse2.4 Gene Expression Profiling; References; 3: Histology; 3.1 Immunohistochemistry; 3.2 Hypoplastic MDS; 3.3 MDS withBone Marrow Fibrosis (MDSf); References; 4: Cytogenetics ofMDS; 4.1 Introduction; 4.2 Chromosome Banding Analysis; 4.3 Fluorescence InSitu Hybridization; 4.4 Value ofFISH inMDS withaNormal Karyotype or Insufficient Metaphase Yield; 4.5 FISH-Analysis ofPeripheral Blood; 4.6 CD34+ FISH ofPeripheral Blood; 4.6.1 Background; 4.6.2 Method; 4.6.3 CD34+FISH-Trial.
|
|
|
:
|
4.6.4 Clonal Evolution by FISH4.6.5 Conclusions fortheApplication ofpb FISH inMDS; 4.7 Complex Abnormalities andKaryotype Evolution; 4.8 Clinical Scores: Scoring-ƯSystems withCytogenetic Components inMDS; References; 5: Chronic Myelomonocytic Leukemia (CMML); 5.1 Introduction; 5.2 CMML Diagnostic; 5.2.1 WHO 2016 Diagnostic Criteria; 5.2.2 Peripheral Blood Cells; 5.2.3 Immunophenotyping ofBlood Monocytes; 5.2.4 Bone Marrow Examination; 5.2.5 Cytogenetic Abnormalities; 5.2.6 Molecular Analyses; 5.3 CMML Clinical Heterogeneity; 5.3.1 Common Presentation.
|
|
|
:
|
5.3.2 Therapy-Related CMML5.3.3 Autoimmune andInflammatory Diseases; 5.3.4 Eosinophilic Tissue Infiltration; 5.3.5 Second Primary Malignancy; 5.3.6 AML Transformation; 5.3.7 Associated Plasmacytoid Dendritic Cell Neoplasm; 5.3.8 Associated Systemic Mastocytosis; 5.3.9 Associated Histiocytic Disorder; 5.4 CMML Pathophysiology; 5.4.1 The Cell ofOrigin; 5.4.2 Growth Factor Hypersensitivity; 5.4.3 The Role ofEpigenetic Alterations; 5.4.4 Intrinsic Defects inMonocyte Properties; 5.4.5 The Suspected Role oftheMicroenvironment; 5.4.6 CMML Risk Stratification.
|
| Abstract
|
:
|
This book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.
|
| Subject
|
:
|
Myelodysplastic syndromes-- Diagnosis.
|
| Subject
|
:
|
Myelodysplastic syndromes-- Treatment.
|
| Subject
|
:
|
Haematology.
|
| Subject
|
:
|
HEALTH FITNESS-- Diseases-- General.
|
| Subject
|
:
|
Hematology.
|
| Subject
|
:
|
MEDICAL-- Clinical Medicine.
|
| Subject
|
:
|
MEDICAL-- Diseases.
|
| Subject
|
:
|
MEDICAL-- Evidence-Based Medicine.
|
| Subject
|
:
|
MEDICAL-- Internal Medicine.
|
| Subject
|
:
|
Medicine.
|
| Subject
|
:
|
Oncology.
|
| Subject
|
:
|
Oncology.
|
| Dewey Classification
|
:
|
616.4/1
|
| LC Classification
|
:
|
RC645.73
|
| Added Entry
|
:
|
Fenaux, Pierre
|
|
|
:
|
Platzbecker, Uwe
|